DSGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DS

Mkt Cap

$644.9M

Volume

697.92K

Next Earnings

November 4th

Loading chart

DS

DSGNDesign Therapeutics, Inc. Common Stock

DSGN

Pay with—

Available Balance0.00

DS

Mkt Cap

$645.2M

Volume

697.92K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich AtaxiaDesign Therapeutics announced positive Phase 1/2 data from its RESTORE-FA trial showing DT-216P2 demonstrated dose-dependent clinical improvements in Friedreich ataxia patients after four weeks of treatment, including improvements in mFARS scores, upright stability, and fatigue. The drug showed comprehensive biomarker activity with 65% increase in FXN mRNA and 22-27% increase in FXN protein levels. The company plans to advance toward registrational development with updates expected in Q4 2026.GlobeNewswire Inc. · May 18, 2026

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026Design Therapeutics announced it will present Phase 1/2 RESTORE-FA trial data for DT-216P2, its experimental treatment for Friedreich's ataxia, on May 18, 2026. The company is advancing multiple clinical-stage programs using its GeneTAC gene-targeted chimera platform, with trials ongoing for corneal dystrophy and myotonic dystrophy treatments, and dosing expected to begin for its Huntington's disease program in the first half of 2026.GlobeNewswire Inc. · May 17, 2026

Design Therapeutics to Participate in Upcoming Investor ConferencesDesign Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.GlobeNewswire Inc. · Nov 26, 2025

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceCARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.GlobeNewswire Inc. · May 7, 2024

Design Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingThe Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. FTC Solar The Trade: FTC Solar, Inc. (NASDAQ: FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930. What’s Happening: On March 13, FTC ...Benzinga · Mar 26, 2024

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsNew Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025GlobeNewswire Inc. · Mar 19, 2024

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateCARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.GlobeNewswire Inc. · Mar 12, 2024

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowDesign Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Zacks Investment Research · Dec 18, 2023

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company TurnaroundGlobeNewswire Inc. · Nov 13, 2023

Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively BuyingThe Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Carmell Therapeutics The Trade: Carmell Therapeutics Corporation (NASDAQ: CTCX) President and CEO Randolph W Hubbell acquired a total of 2,750 shares an average price of $3.67. To acquire these shares, it cost around $10,091. What’s Happening: Carmell Therapeutics announced a merger with Axoloti Biologix. What Carmell Therapeutics Does: Carmell Therapeutics Corp is a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based ...Benzinga · Aug 31, 2023

to start trading

DS

DSGNDesign Therapeutics, Inc. Common Stock

DSGN

Pay with—

Available Balance0.00

Your PositionYou don't own any DSGN yet.

Related Tickers

Earnings